Get Live Data

The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’View Video
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin AmericaView Video

Latest Share Chat

  2. Share Prices
  3. N4 Pharma Plc Share Price
  4. N4 Pharma Plc Share News
  5. UK shareholder meetings calendar - next 7 days

Pin to quick picksN4 Pharma Plc Share News (N4P)

N4 Pharma Plc Information

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.775
Bid: 0.75
Ask: 0.80
Change: 0.00 (0.00%)
Spread: 0.05 (6.667%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 0.775
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK shareholder meetings calendar - next 7 days

Wed, 17th Mar 2021 16:31

Thursday 18 March 
4D Pharma PLCGM re Longevity merger
Amino Technologies PLCAGM
BigDish PLCAGM
CML Microsystems PLCGM re return of capital
Drum Income Plus REIT PLCAGM
Idox PLCAGM
Impax Asset Management Group PLCAGM
Shield Therapeutics PLCGM re share placing
Signature Aviation PLCGM re acquisition
Sureserve Group PLCAGM
Tullow Oil PLCGM re disposals in Equatorial Guinea and Gabon
Friday 19 March 
Chenavari Toro Income Fund LtdAGM
Red Rock Resources PLCGM re Kansai acquisition
Monday 22 March 
Gresham House Renewable Energy VCT 1 PLCAGM
Gresham House Renewable Energy VCT 2 PLCAGM
Pacific Horizon Investment Trust PLCGM
Highway Capital PLCAGM
Tuesday 23 March 
Blackrock North American Income Trust PLCAGM
Crest Nicholson Holdings PLCAGM
Quartix Holdings PLCAGM
Secured Income Fund PLCGM re B share scheme
Standard Life Private Equity Trust PLCAGM
Wednesday 24 March 
Arden Partners PLCAGM
BlackRock Throgmorton Trust PLCAGM
Mitchells & Butlers PLCAGM
N4 Pharma PLCAGM
Oxford Biodynamics PlcAGM
Pantheon Resources PLCAGM
Rights & Issues Investment Trust PLCAGM
Tertiary Minerals PLCGM re disapplying pre-emptive rights
  
Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
9 Mar 2023 14:32

EARNINGS SUMMARY: Franchise Brands blooms; Tlou Energy loss widens

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
17 Jan 2023 16:23

TRADING UPDATES: hVIVO wins contract; Dev Clever cancels shares

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
18 Nov 2022 11:16

AIM WINNERS & LOSERS: Parsley Box to exit AIM as shares wilt since IPO

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
18 Nov 2022 11:02

N4 Pharma plummets on broker offer to raise up to GBP1 million

(Alliance News) - N4 Pharma PLC shares plummeted on Friday, after it raised GBP1.0 million through a placing of 50.0 million shares and announced a broker offer to raise up to GBP1.0 million.

Read more
18 Nov 2022 08:11

N4 Pharma shares tumble following placing, broker offer announcement

(Sharecast News) - Shares in pharmaceutical company N4 Pharma tumbled on Friday after the group said it had raised £1.0m via the placing of 50.0m new ordinary shares of 0.4p each and detailed a broker offer aimed at raising as much as another £1.0m.

Read more
1 Nov 2022 17:06

IN BRIEF: N4 Pharma expands patent application claims for Nuvec

N4 Pharma PLC - Derby, England-based pharmaceutical company focused on developing Nuvec, a delivery system for vaccines and cancer treatments - Provides a patent application update for Nuvec.

Read more
4 Oct 2022 13:32

N4 Pharma reports success in recent 'Nuvec' testing

(Sharecast News) - Specialist pharmaceutical company N4 Pharma announced success in its in-vitro testing of its 'Nuvec' drug delivery system on Tuesday, loaded with two small interfering RNA (siRNA) probes.

Read more
4 Oct 2022 11:19

AIM WINNERS & LOSERS: N4's Nuvec success; Watkin Jones tumbles

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
4 Oct 2022 10:38

N4 Pharma announces successful test in next stage of Nuvec development

(Alliance News) - N4 Pharma PLC on Tuesday announced successful in vitro testing of Nuvec when loaded with two small interfering siRNA probes.

Read more
4 Oct 2022 08:46

LONDON MARKET OPEN: Stocks rise as market sentiment recovers

(Alliance News) - Stock prices in London opened sharply higher on Tuesday, lifted by more positive market sentiment following the UK government's tax U-turn, as well as some positive trading updates.

Read more
29 Sep 2022 15:09

EARNINGS UPDATES: Crestchic raises outlook on record year-to-date

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
29 Sep 2022 12:11

N4 Pharma reduces losses as Nuvec development continues

(Sharecast News) - Specialist pharmaceutical company N4 Pharma reduced its operating loss in the first half, it reported on Thursday, to £0.75m from £0.97m a year earlier.

Read more
14 Sep 2022 12:03

IN BRIEF: N4 completes testing on loading Nuvec drug with siRNA probes

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company - Completes initial testing on loading its Nuvec treatment with two generic siRNA probes at the same time. siRNA can prevent cells from communicating, potentially preventing cancer cells from replicating. N4 are now undertaking experiments using siRNA sequences against known oncology targets. This includes in vitro using a lung cancer cell line and, after that, in vivo studies in mice. Chief Executive Officer Nigel Theobald said: "We have now identified a very strong commercial point of difference for Nuvec in that it can be successfully loaded with at least two siRNA genes".

Read more
15 Jul 2022 21:26

TRADING UPDATES: Premier Miton assets dip; Challenger Energy CFO quits

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
15 Jul 2022 13:23

N4 Pharma upbeat on latest tumour suppression study data

(Sharecast News) - Specialist pharmaceutical developer N4 Pharma updated the market on its recent preclinical study with TNF alpha on Friday.

Read more
123456789

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.